It is reported on clinical and haemodynamic results with
Bonnecor, a new
antiarrhythmic drug with class I and IV properties, on 68 test persons in parenteral and
oral administration. The haemodynamic acute investigations (dosage 2 x 0.1 to 1 x 0.3 mg/kg
body weight) which were performed on 10 test persons with compensated
heart diseases did not show any negative haemodynamic effects of
Bonnecor at rest and on exercition. The chronic effect on
ventricular extrasystoles of the degrees of severity mostly II-IV were investigated in the open experiment on 17 patients as well as on 3 patients with supraventricular dysrhythmias and on 30 patients with
ventricular extrasystoles Lown III-IV in the single blind cross-over experiments to
verapamil retard. A clinically relevant result with regard to the reduction of the
ventricular extrasystole about 75% was found in 23% of the patients (open study) and 33.3% of the patients (cross-over), respectively. The reduction of the
ventricular extrasystole was significant compared with the empty value. Under the influence of
verapamil a significant reduction of the
ventricular extrasystole could not be verified, the differences between
Verapamil and
Bonnecor were, however, not to be ascertained statistically. The effect of
Bonnecor on couplets and volleys was clinically relevant in 52 and 46%, respectively, of the patients (reduction greater than or equal to 93%) and approximately corresponds to the results with other
antiarrhythmic drugs. The tolerability is to be estimated as relatively good.(ABSTRACT TRUNCATED AT 250 WORDS)